Phathom Pharmaceuticals Q4 2023 Earnings Report $8.59 +0.22 (+2.63%) (As of 09:51 AM ET) Earnings HistoryForecast Phathom Pharmaceuticals EPS ResultsActual EPS-$0.80Consensus EPS -$0.92Beat/MissBeat by +$0.12One Year Ago EPS-$1.33Phathom Pharmaceuticals Revenue ResultsActual Revenue$0.68 millionExpected Revenue$0.93 millionBeat/MissMissed by -$250.00 thousandYoY Revenue GrowthN/APhathom Pharmaceuticals Announcement DetailsQuarterQ4 2023Date3/7/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptPress ReleasePHAT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Phathom Pharmaceuticals Earnings HeadlinesPhathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up Following Insider Buying ActivityDecember 18 at 1:07 AM | americanbankingnews.comPhathom Pharmaceuticals Submits Citizen Petition to FDA for Correction of Orange Book Listings for VOQUEZNA TabletsDecember 13, 2024 | americanbankingnews.comHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.December 18, 2024 | Porter & Company (Ad)Phathom Pharmaceuticals: Securing Long-term Exclusivity for Growth PotentialDecember 12, 2024 | markets.businessinsider.comPhathom Pharmaceuticals: Undervalued Opportunity with Strategic Moves for Extended ExclusivityDecember 12, 2024 | markets.businessinsider.comDo You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?December 12, 2024 | msn.comSee More Phathom Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phathom Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your email. Email Address About Phathom PharmaceuticalsPhathom Pharmaceuticals (NASDAQ:PHAT), biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.View Phathom Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Cintas (12/19/2024) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
